Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.

Qian M, Song NJ

Open source

DOI
10.26355/eurrev_201807_15426
Published
2018 Jul
Container
European review for medical and pharmacological sciences
Publisher
Not recorded
Open access
unknown

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.26355/eurrev_201807_15426,
  title = {Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.},
  author = {Qian M and Song NJ},
  year = {2018},
  journal = {European review for medical and pharmacological sciences},
  doi = {10.26355/eurrev_201807_15426},
  url = {https://doi.org/10.26355/eurrev_201807_15426}
}

RIS

TY  - JOUR
TI  - Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.
AU  - Qian M
AU  - Song NJ
PY  - 2018
JO  - European review for medical and pharmacological sciences
DO  - 10.26355/eurrev_201807_15426
UR  - https://doi.org/10.26355/eurrev_201807_15426
ER  - 

APA

M, Q., & NJ, S. (2018). Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.. European review for medical and pharmacological sciences. https://doi.org/10.26355/eurrev_201807_15426

Source records